Loading question...
You are in free guest mode. Timed Practice Revision List Attempt History Progress Tracking Create a free account to unlock these tools
Prev Next
CELPIP Practice Reading: Reading for Viewpoints ID: #60212 Hard Cheaper Copies, Steady Shelves

Read the following editorial from a website.

Before a new medicine reaches pharmacy shelves, its maker has usually spent years and a great deal of money on research and testing. In return, the company receives a patent, a period during which no one else may sell the same drug. When the patent ends, other companies may make generic copies with the same active ingredient, usually at a far lower price. This week the province proposed two changes: pharmacists would have to fill prescriptions with the cheapest generic available, and the province would buy generics in bulk through a single contract. We support the first idea, but we have doubts about the second as written.

Cornelius Lindberg, who represents brand-name drug makers through their national association, warns that the plan sends the wrong signal. “Every drug that works was paid for by the ten that failed in testing,” he told reporters. He argues that if provinces squeeze prices too hard, companies will launch new medicines here later than in other countries. Carmela Vallee, who heads a consumer group for patients, says that argument mixes up two different stages. Once a patent has expired, she points out, the research has already been rewarded, and patients should not keep paying brand prices for a copy that works the same way. She estimates that families with chronic conditions could save hundreds of dollars a year.

Hamza Mehra, a pharmacist in a small town, supports substitution but worries about the bulk contract. If the province buys each drug from one supplier and that factory has a problem, he says, shelves across the province could be empty within weeks. He wants at least two suppliers for every drug on the list. Dr. Eleanor Braun, a family physician, notes that for a small number of medicines, such as some drugs for epilepsy, even a slight change in the product can unsettle a patient who has been stable for years. She wants doctors to be able to write “no substitution” on a prescription when they give a medical reason.

We agree with Vallee that an expired patent should mean a lower price. Lindberg’s warning about launch dates deserves our attention, but it belongs in federal debates over patents, not in this one. Our province should require substitution, with Braun’s medical exception written into the rule. It should also rewrite the bulk contract so that every drug has at least two suppliers, as Mehra asks. Savings mean little to us if the medicine is not there.

Using the drop-down menu (▾), choose the best option according to the information given on the website.

This editorial is mainly about 1.
.

Who most clearly doubts that relying on a single supplier is safe? 2.
.

Carmela Vallee’s position would most likely be supported by 3.
.

What outcome does Dr. Eleanor Braun’s proposal call for? 4.
.

The editorial’s attitude toward the bulk-buying plan is best described as 5.
.

The following is a comment by a visitor to the website page. Complete the comment by choosing the best option to fill in each blank.

I take a daily pill for my thyroid, and my pharmacist switched me to a generic two years ago without any fuss. Cornelius Lindberg predicts that drug companies would 6.
if prices fall too far. Carmela Vallee thinks families with chronic conditions could save 7.
, which matches my own receipts. My neighbour pays the full brand price for her heart medicine because nobody ever told her a cheaper copy might exist. Dr. Braun names drugs for 8.
as a case where switching needs care. The editors say one of Lindberg’s concerns belongs in 9.
, and I agree that it is a separate fight. I had not known that a generic copy must contain 10.
, a fact I plan to repeat to my mother this weekend.

With a free account: Retry and compare every attempt.
Saving...